FNCHQ
Price:
$10.35
Market Cap:
$16.62M
Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. Its platform includes Human-First Discovery that enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms. The company was founded by Mark Smith, Andrew Noh, Tom Borody and Zain Kassam in 2014 and is headquartered in Boston, MA.
Industry
Biotechnology
IPO Date
2021-03-18
Stock Exchange
OTC
Ticker
FNCHQ
According to Finch Therapeutics Group, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.17. This represents a change of 173.40% compared to the average of -0.43 of the last 4 quarters.
The mean historical PE Ratio of Finch Therapeutics Group, Inc. over the last ten years is -426.13. The current -1.17 PE Ratio has changed -72.54% with respect to the historical average. Over the past ten years (40 quarters), FNCHQ's PE Ratio was at its highest in in the June 2024 quarter at -0.11. The PE Ratio was at its lowest in in the September 2021 quarter at -465.95.
Average
-426.13
Median
-125.43
Minimum
-1516.28
Maximum
-0.08
Discovering the peaks and valleys of Finch Therapeutics Group, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.59%
Maximum Annual PE Ratio = -0.08
Minimum Annual Increase = -98.71%
Minimum Annual PE Ratio = -1516.28
| Year | PE Ratio | Change |
|---|---|---|
| 2024 | -1.31 | 1.59% |
| 2023 | -0.08 | -98.71% |
| 2022 | -6.00 | -97.55% |
| 2021 | -244.85 | -68.94% |
| 2020 | -788.29 | -48.01% |
The current PE Ratio of Finch Therapeutics Group, Inc. (FNCHQ) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-2.46
5-year avg
-208.11
10-year avg
-426.13
Finch Therapeutics Group, Inc.’s PE Ratio is greater than Biomea Fusion, Inc. (-3.61), greater than Connect Biopharma Holdings Limited (-1.47), greater than Edgewise Therapeutics, Inc. (-25.37), greater than Werewolf Therapeutics, Inc. (-1.31), less than ImageneBio Inc (-0.96), less than Pasithea Therapeutics Corp. (-0.21), less than Quoin Pharmaceuticals, Ltd. (-0.47),
| Company | PE Ratio | Market cap |
|---|---|---|
| -3.61 | $129.42M | |
| -1.47 | $81.22M | |
| -25.37 | $5.05B | |
| -1.31 | $46.80M | |
| -0.96 | $56.62M | |
| -0.21 | $16.93M | |
| -0.47 | $14.08M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Finch Therapeutics Group, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Finch Therapeutics Group, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Finch Therapeutics Group, Inc.'s PE Ratio?
How is the PE Ratio calculated for Finch Therapeutics Group, Inc. (FNCHQ)?
What is the highest PE Ratio for Finch Therapeutics Group, Inc. (FNCHQ)?
What is the 3-year average PE Ratio for Finch Therapeutics Group, Inc. (FNCHQ)?
What is the 5-year average PE Ratio for Finch Therapeutics Group, Inc. (FNCHQ)?
How does the current PE Ratio for Finch Therapeutics Group, Inc. (FNCHQ) compare to its historical average?